NCT06777472Not yet recruiting
Clinical Study of Lung-benefiting Moxibustion Reduce Exacerbations of Asthma
Clinical Study on Reducing Exacerbations of Asthma by Lung-benefiting Moxibustion Based on "Winter Disease Cured in Summer"
Source: ClinicalTrials.gov · Last updated 15 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
For patients with poor asthma control, on the basis of treatment guided by GINA guidelines, lung-benefiting moxibustion treatment will be given, and it will be applied 10 days before "early onset", once every 10 days, and the follow-up was 45 weeks, 1 cycle per year, for 2 consecutive cycles (2 years). The annual number of flare-up of asthma patients will be used as the main outcome index to evaluate the clinical effect of lung-benefiting moxibustion on reducing exacerbations of asthma. By observing immunoglobulin, T cell subsets and other indicators, the advantage population and mechanism of moxibustion in treating patients with poor asthma control will be clarified.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 384 (estimated)
- First submitted
- 29 Dec 2024
- Start date
- Jul 2025
- Primary completion date
- Sept 2026
- Lead sponsor
- Cuiling Feng
- Diseases
- Asthma
- NCT number
- NCT06777472
What you commit to
- Study type: Interventional
- Planned participants: 384
- From Jul 2025 to the primary completion date, Sept 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients participating in other clinical trials within 1 month prior to enrollment;
- Received TCM external treatment such as lung-benefiting moxibustion for 1 year;
Other illness
- Patients combined with pulmonary abscess, pulmonary fibrosis, active pulmonary tuberculosis, bronchiectasis or other lung diseases;
- Patients with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, cardiac functional classification≥III, stroke, cerebral hemorrhage, etc.)；
- Patients with severe liver diseases (liver cirrhosis, portal hypertension, bleeding due to esophageal and gastric varices, etc.) or severe kidney diseases (renal dialysis, kidney transplantation, etc.)；
- Patients with confusion, various mental disorders, etc., who are unable to communicate normally;
- Patients allergic to moxibustion drugs, smoke, etc.
Other
- Pregnant and lactating women;
- Patients with heat phlegm pattern through TCM pattern differentiation；
Who the study is looking for
- Patients who meet the diagnosis of asthma (remission);
- Patients with poor clinical control;
- Age 18-80 years old;
- Voluntarily undergo treatment and sign an informed consent form;
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.